Search results for "Niemann–Pick disease"

showing 10 items of 13 documents

Psychiatric and neurological symptoms in patients with Niemann-Pick disease type C (NP-C): Findings from the International NPC Registry

2017

Objectives: Niemann-Pick disease type C (NP-C) is a rare inherited neurovisceral disease that should be recognised by psychiatrists as a possible underlying cause of psychiatric abnormalities. This...

AdultMalePsychosismedicine.medical_specialtyPediatricsInternationalityAdolescentDiseaseYoung Adult03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesmedicinePsychiatric abnormalitiesHumansIn patientProspective StudiesRegistriesAge of OnsetChildPsychiatryBiological PsychiatryAgedNiemann–Pick disease type Cbusiness.industryMental Disordersnutritional and metabolic diseasesNiemann-Pick Disease Type CMiddle Agedmedicine.disease030227 psychiatryPsychiatry and Mental healthSchizophreniaChild PreschoolFemalebusinessThe World Journal of Biological Psychiatry
researchProduct

Niemann-Pick disease type C symptomatology: an expert-based clinical description

2013

Niemann-Pick disease type C (NP-C) is a rare, progressive, irreversible disease leading to disabling neurological manifestations and premature death. The estimated disease incidence is 1:120,000 live births, but this likely represents an underestimate, as the disease may be under-diagnosed due to its highly heterogeneous presentation. NP-C is characterised by visceral, neurological and psychiatric manifestations that are not specific to the disease and that can be found in other conditions. The aim of this review is to provide non-specialists with an expert-based, detailed description of NP-C signs and symptoms, including how they present in patients and how they can be assessed. Early dise…

MalePediatricsmedicine.medical_specialtyPsychosisAtaxiaReviewDiseaseGelastic cataplexyDysarthriaDiagnosisMiglustatHumansMedicineGenetics(clinical)Pharmacology (medical)Lysosomal lipid storage diseaseVertical supranuclear gaze palsyCognitive declineGenetics (clinical)DystoniaMedicine(all)Niemann–Pick disease type Cbusiness.industryNiemann-Pick disease type CNiemann-Pick Disease Type CGeneral Medicinemedicine.diseaseDystoniaCognitive impairmentSplenomegalyAtaxiaFemalemedicine.symptombusinessmedicine.drugOrphanet Journal of Rare Diseases
researchProduct

Recommendations on the diagnosis and management of Niemann-Pick disease type C

2009

Niemann-Pick disease type C (NP-C) is a lysosomal storage disease in which impaired intracellular lipid trafficking leads to excess storage of cholesterol and glycosphingolipids in the brain and other tissues. it is characterized clinically by a variety of progressive, disabling neurological symptoms including clumsiness, limb and gait ataxia, dysarthria, dysphagia and cognitive deterioration (dementia). Until recently, there has been no disease-modifying therapy available for NP-C, with treatment limited to supportive measures. In most countries, NP-C is managed through specialist centers, with non-specialist support provided locally. However, effective patient Support is hampered by the a…

Adultmedicine.medical_specialtyNeurology1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistry03 medical and health sciencesDysarthriaYoung Adult0302 clinical medicineEndocrinology1311 GeneticsGeneticsLysosomal storage diseasemedicine1312 Molecular BiologyDementiaHumansMass ScreeningIntensive care medicineChildMolecular BiologyMass screening030304 developmental biology0303 health sciencesNiemann–Pick disease type Cbusiness.industryInfant NewbornInfantNiemann-Pick Disease Type CMiddle Agedmedicine.disease3. Good health1310 Endocrinology2712 Endocrinology Diabetes and Metabolism10036 Medical ClinicChild PreschoolPhysical therapyGait Ataxiamedicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Plasma lysosphingomyelin demonstrates great potential as a diagnostic biomarker for Niemann-Pick disease type C in a retrospective study.

2015

Niemann-Pick disease type C (NP-C) is a devastating, neurovisceral lysosomal storage disorder which is characterised by variable manifestation of visceral signs, progressive neuropsychiatric deterioration and premature death, caused by mutations in the NPC1 and NPC2 genes. Due to the complexity of diagnosis and the availability of an approved therapy in the EU, improved detection of NP-C may have a huge impact on future disease management. At the cellular level dysfunction or deficiency of either the NPC1 or NPC2 protein leads to a complex intracellular endosomal/lysosomal trafficking defect, and organ specific patterns of sphingolipid accumulation. Lysosphingolipids have been shown to be e…

MalePathologyEndocrinology Diabetes and Metabolismlcsh:MedicineDiseaseBiochemistryEndocrinologySphingosineTandem Mass Spectrometrylcsh:ScienceBlood Specimen CollectionMultidisciplinaryNiemann-Pick Disease Type CInherited Metabolic DisordersLipidsBiomarker (medicine)FemaleNiemann–Pick diseaseNiemann-Pick diseaseResearch ArticleAdultmedicine.medical_specialtyAdolescentPhosphorylcholineYoung AdultDiagnostic MedicineGeneticsmedicineHumansSphingolipidosisClinical geneticsMolecular BiologyEdetic AcidAgedRetrospective StudiesMedicine and health sciencesSphingolipidsNiemann–Pick disease type Cbusiness.industryHeparinlcsh:RCase-control studyPsychosineReproducibility of ResultsBiology and Life SciencesRetrospective cohort studymedicine.diseaseSphingolipidCase-Control StudiesAutosomal recessive diseasesMetabolic Disorderslcsh:QNPC1businessLysosphingomyelinBiomarkersPloS one
researchProduct

Miglustat in patients with Niemann-Pick disease Type C (NP-C): A multicenter observational retrospective cohort study

2009

Miglustat has been shown to stabilize disease progression in children, juveniles and adults with Niemann-Pick disease type C (NP-C), a rare genetic disorder characterized by progressive neurological deterioration. We report findings from a retrospective observational cohort study assessing the effects of miglustat on neurological disease progression in patients treated in the clinical practice setting. Data from all NP-C patients prescribed miglustat at 25 expert centers were evaluated using a disease disability scale. The scale analyzed four key parameters of neurological disease progression in NP-C (ambulation, manipulation, language, swallowing). Mean individual parameter scores and a co…

MalePediatricsmedicine.medical_specialty1-Deoxynojirimycin1303 BiochemistryAdolescentEndocrinology Diabetes and Metabolism610 Medicine & healthDiseaseBiochemistryCohort StudiesEndocrinology1311 GeneticsMiglustat1312 Molecular BiologyGeneticsHumansMedicineEnzyme InhibitorsChildMolecular BiologyRetrospective StudiesNiemann–Pick disease type Cbusiness.industryNiemann-Pick Disease Type CRetrospective cohort studymedicine.disease1310 EndocrinologyClinical trial2712 Endocrinology Diabetes and MetabolismTreatment Outcome10036 Medical ClinicCohortFemalebusinessNiemann–Pick diseaseCohort studymedicine.drugMolecular Genetics and Metabolism
researchProduct

Critical assessment of chitotriosidase analysis in the rational laboratory diagnosis of children with Gaucher disease and Niemann-Pick disease type A…

2006

Laboratory diagnosis of lysosomal storage disorders, especially sphingomyelinase deficiency (Niemann–Pick disease type A/B) and Niemann–Pick disease type C (NPC) can be challenging. We therefore aimed to analyse the feasibility of first-step screening with specific chitotriosidase cut-off values in children ≤ 10 years of age with visceral organomegaly (hepatomegaly, splenomegaly, or hepatosplenomegaly) in whom a storage disorder was suspected. We conducted a retrospective, cross-sectional, referral, single-centre study to assess diagnostic test properties in 106 individuals. Median chitotriosidase activity was 12 655 nmol/h per ml (interquartile range 4693–20982) in Gaucher disease (GD); 78…

medicine.medical_specialtyHepatosplenomegalyGastroenterologySensitivity and SpecificityOrganomegalyCentral nervous system diseaseDiagnosis DifferentialInterquartile rangePredictive Value of TestsInternal medicineGene DuplicationGenotypeGeneticsMedicineGlycogen storage diseaseHumansChildGenetics (clinical)Retrospective StudiesGaucher Diseasebusiness.industryInfantNiemann-Pick Disease Type CNiemann-Pick Disease Type BNiemann-Pick Disease Type Amedicine.diseaseEndocrinologyHexosaminidasesChemistry ClinicalChild Preschoolmedicine.symptomDifferential diagnosisbusinessNiemann–Pick diseaseJournal of inherited metabolic disease
researchProduct

Longitudinal data from the international registry for Niemann-Pick disease type C (NPC)

2014

(0.69) years. Among 74/80 patients with available data, 10 (14%) patients had early-infantile (aged b2 years), 24 (32%) late-infantile (2 to b6 years), 24 (32%) juvenile (6 to b15 years), and 16 (22%) adolescent/ adult (≥15 years) onset of neurological manifestations. Mean (95%CI) composite disability scores at enrolment and last follow-up visit were 0.39 (0.34, 0.45; N = 75) and 0.45 (0.39, 0.51; N = 76), respectively. A total of 52/72 (72%) patients were categorised as ’improved/stable’ ;2 0/ 72 (28%) were categorised as ‘progressed’. Safety and tolerability findings for miglustat were in line with previous published data. A low proportion of patients had chronic diarrhoea during follow u…

Pediatricsmedicine.medical_specialtyNiemann–Pick disease type CLongitudinal databusiness.industryEndocrinology Diabetes and MetabolismChronic diarrhoeamedicine.diseaseBiochemistryEndocrinologyTolerabilityMiglustatGeneticsMedicinebusinessMolecular Biologymedicine.drugMolecular Genetics and Metabolism
researchProduct

Baseline data from a prospective international disease registry for Niemann-Pick disease type C

2011

medicine.medical_specialtyNiemann–Pick disease type Cbusiness.industryEndocrinology Diabetes and MetabolismBaseline datamedicine.diseaseBiochemistryEndocrinologyDisease registryInternal medicineGeneticsmedicinebusinessMolecular BiologyMolecular Genetics and Metabolism
researchProduct

Update From the International Registry for Niemann-Pick Disease Type C (NP-C) in Clinical Practice

2012

Clinical PracticePediatricsmedicine.medical_specialtyEndocrinologyNiemann–Pick disease type Cbusiness.industryEndocrinology Diabetes and MetabolismGeneticsmedicinemedicine.diseasebusinessMolecular BiologyBiochemistryMolecular Genetics and Metabolism
researchProduct

Use of 2 hydroxypropyl-beta-cyclodextrin therapy in two adult Niemann Pick Type C patients

2016

0301 basic medicineNiemann–Pick disease type CFatal outcomebusiness.industryBeta-CyclodextrinsPharmacologyIntrathecalmedicine.disease03 medical and health sciences2-Hydroxypropyl-beta-cyclodextrin030104 developmental biology0302 clinical medicine2 hydroxypropyl β cyclodextrinNeurologyToxicitymedicineNeurology (clinical)Metabolic diseasebusiness030217 neurology & neurosurgeryJournal of the Neurological Sciences
researchProduct